Wendy Perrow
Net worth: - $ as of 2024-03-30
Profile
Wendy Perrow served as President & Chief Executive Officer at Alba Therapeutics Corp.
from 2013 to 2016, and as Chief Executive Officer at AsclepiX Therapeutics LLC from 2016 to 2020.
She also worked as a Principal at Merck & Co., Inc. from 1989 to 2003, and as Vice President-Marketing & Sales at Leadiant Biosciences, Inc. from 2004 to 2007.
Ms. Perrow is currently an Independent Director at Inotiv, Inc. and a Trustee at A Dinner of Hope, Inc. She will also serve as an Independent Non-Executive Director at Femasys, Inc. from 2022 to 2023.
Ms. Perrow received her undergraduate degree from Duke University and Eastern Illinois University, and her MBA from The Fuqua School of Business.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
FEMASYS, INC.
-.--% | 2023-07-27 | 0 ( -.--% ) | - $ | 2024-03-30 |
Former positions of Wendy Perrow
Companies | Position | End |
---|---|---|
FEMASYS INC. | Director/Board Member | 2023-11-07 |
AsclepiX Therapeutics LLC
AsclepiX Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services AsclepiX Therapeutics LLC engages in biologics and drug development technology. It specializes in anti-angiogenesis therapy, ophthalmology, oncology, and immunology. The company was founded by Jordan J. Green and Aleksander S. Popel and is headquartered in Baltimore, MD. | Chief Executive Officer | 2019-12-31 |
Alba Therapeutics Corp.
Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | Chief Executive Officer | 2015-12-31 |
Leadiant Biosciences, Inc.
Leadiant Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Leadiant Biosciences, Inc. operates as a research-based pharmaceutical company. It develops and commercializes medicines for rare diseases. The company was founded in 1989 by Claudio Cavazza and is headquartered in Gaithersburg, MD. | Sales & Marketing | 2007-12-30 |
MERCK & CO., INC. | Corporate Officer/Principal | - |
Training of Wendy Perrow
Duke University | Undergraduate Degree |
Eastern Illinois University | Undergraduate Degree |
The Fuqua School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
MERCK & CO., INC. | Health Technology |
INOTIV, INC. | Commercial Services |
FEMASYS INC. | Electronic Technology |
Private companies | 4 |
---|---|
Alba Therapeutics Corp.
Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | Health Technology |
Leadiant Biosciences, Inc.
Leadiant Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Leadiant Biosciences, Inc. operates as a research-based pharmaceutical company. It develops and commercializes medicines for rare diseases. The company was founded in 1989 by Claudio Cavazza and is headquartered in Gaithersburg, MD. | Health Technology |
A Dinner of Hope, Inc. | |
AsclepiX Therapeutics LLC
AsclepiX Therapeutics LLC Miscellaneous Commercial ServicesCommercial Services AsclepiX Therapeutics LLC engages in biologics and drug development technology. It specializes in anti-angiogenesis therapy, ophthalmology, oncology, and immunology. The company was founded by Jordan J. Green and Aleksander S. Popel and is headquartered in Baltimore, MD. | Commercial Services |
- Stock Market
- Insiders
- Wendy Perrow